189 related articles for article (PubMed ID: 25730310)
1. Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study.
Perry MR; Prajapati VK; Menten J; Raab A; Feldmann J; Chakraborti D; Sundar S; Fairlamb AH; Boelaert M; Picado A
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003518. PubMed ID: 25730310
[TBL] [Abstract][Full Text] [Related]
2. Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study.
Das S; Mandal R; Rabidas VN; Verma N; Pandey K; Ghosh AK; Kesari S; Kumar A; Purkait B; Lal CS; Das P
PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005060. PubMed ID: 27776123
[TBL] [Abstract][Full Text] [Related]
3. Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis.
Perry MR; Wyllie S; Raab A; Feldmann J; Fairlamb AH
Proc Natl Acad Sci U S A; 2013 Dec; 110(49):19932-7. PubMed ID: 24167266
[TBL] [Abstract][Full Text] [Related]
4. Arsenic, antimony, and Leishmania: has arsenic contamination of drinking water in India led to treatment- resistant kala-azar?
Perry M; Wyllie S; Prajapati V; Menten J; Raab A; Feldmann J; Chakraborti D; Sundar S; Boelaert M; Picado A; Fairlamb A
Lancet; 2015 Feb; 385 Suppl 1():S80. PubMed ID: 26312902
[TBL] [Abstract][Full Text] [Related]
5. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.
Rijal S; Chappuis F; Singh R; Bovier PA; Acharya P; Karki BM; Das ML; Desjeux P; Loutan L; Koirala S
Trans R Soc Trop Med Hyg; 2003; 97(3):350-4. PubMed ID: 15228258
[TBL] [Abstract][Full Text] [Related]
6. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
[TBL] [Abstract][Full Text] [Related]
7. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
Thakur CP; Narayan S; Ranjan A
Indian J Med Res; 2004 Sep; 120(3):166-72. PubMed ID: 15489554
[TBL] [Abstract][Full Text] [Related]
8. The treatment of visceral leishmaniasis (kala-azar) in India: no obvious signs of long-term success.
Muniaraj M; Paramasivan R; Mariappan T; Arunachalam N; Sinha PK
Trans R Soc Trop Med Hyg; 2012 Dec; 106(12):770-2. PubMed ID: 23102868
[TBL] [Abstract][Full Text] [Related]
9. Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent.
Vanaerschot M; Decuypere S; Downing T; Imamura H; Stark O; De Doncker S; Roy S; Ostyn B; Maes L; Khanal B; Boelaert M; Schönian G; Berriman M; Chappuis F; Dujardin JC; Sundar S; Rijal S
J Infect Dis; 2012 Sep; 206(5):752-5. PubMed ID: 22753945
[TBL] [Abstract][Full Text] [Related]
10. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia.
Diro E; Lynen L; Mohammed R; Boelaert M; Hailu A; van Griensven J
PLoS Negl Trop Dis; 2014 May; 8(5):e2875. PubMed ID: 24854196
[TBL] [Abstract][Full Text] [Related]
11. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.
Sundar S; More DK; Singh MK; Singh VP; Sharma S; Makharia A; Kumar PC; Murray HW
Clin Infect Dis; 2000 Oct; 31(4):1104-7. PubMed ID: 11049798
[TBL] [Abstract][Full Text] [Related]
12. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
13. Sodium stibogluconate-sensitive visceral leishmaniasis in the non-endemic hilly region of Uttarakhand, India.
Verma SK; Ahmad S; Shirazi N; Kusum A; Kaushik RM; Barthwal SP
Trans R Soc Trop Med Hyg; 2007 Jul; 101(7):730-2. PubMed ID: 17382981
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors associated with defaulting from visceral leishmaniasis treatment: analysis under routine programme conditions in Bihar, India.
Kansal S; Chakravarty J; Kumar A; Malaviya P; Boelaert M; Hasker E; Ostyn B; Sundar S
Trop Med Int Health; 2017 Aug; 22(8):1037-1042. PubMed ID: 28594453
[TBL] [Abstract][Full Text] [Related]
15. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India.
Thakur CP; Dedet JP; Narain S; Pratlong F
Trans R Soc Trop Med Hyg; 2001; 95(2):187-9. PubMed ID: 11355558
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.
Gebreyohannes EA; Bhagvathula AS; Abegaz TM; Seid MA
Infect Dis Poverty; 2018 Oct; 7(1):108. PubMed ID: 30340519
[TBL] [Abstract][Full Text] [Related]
17. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
Singh N; Chatterjee M; Sundar S
Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494
[TBL] [Abstract][Full Text] [Related]
18. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
Musa A; Khalil E; Hailu A; Olobo J; Balasegaram M; Omollo R; Edwards T; Rashid J; Mbui J; Musa B; Abuzaid AA; Ahmed O; Fadlalla A; El-Hassan A; Mueller M; Mucee G; Njoroge S; Manduku V; Mutuma G; Apadet L; Lodenyo H; Mutea D; Kirigi G; Yifru S; Mengistu G; Hurissa Z; Hailu W; Weldegebreal T; Tafes H; Mekonnen Y; Makonnen E; Ndegwa S; Sagaki P; Kimutai R; Kesusu J; Owiti R; Ellis S; Wasunna M
PLoS Negl Trop Dis; 2012; 6(6):e1674. PubMed ID: 22724029
[TBL] [Abstract][Full Text] [Related]
19. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
Ritmeijer K; Veeken H; Melaku Y; Leal G; Amsalu R; Seaman J; Davidson RN
Trans R Soc Trop Med Hyg; 2001; 95(6):668-72. PubMed ID: 11816442
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients.
Ribera E; Ocaña I; de Otero J; Cortes E; Gasser I; Pahissa A
Am J Med; 1996 May; 100(5):496-501. PubMed ID: 8644760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
